A real‑world series of 888 patients published in Nature Medicine demonstrates that paired tumor‑normal whole‑genome sequencing (WGS) succeeds in 89% of cases with a median turnaround of six working days and identifies potentially actionable biomarkers in 73% of patients. The study reported that 40% of patients started biomarker‑informed therapies within a year, and biomarker‑matched treatment correlated with a 31% longer median overall survival. Authors argued that WGS offers a comprehensive, tumor‑agnostic diagnostic capable of detecting complex DNA biomarkers and germline variants that panel tests may miss. The paper positions clinical WGS as a practical diagnostic tool in comprehensive cancer centers, particularly for cancers of unknown primary where WGS provided diagnostic solutions or treatment options in two‑thirds of cases.